AffiliationCancer Research UK and University of Manchester, Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.
MetadataShow full item record
AbstractPURPOSE OF REVIEW: To highlight the current antiangiogenic compounds being evaluated as single agents or in association with chemotherapy in the treatment of ovarian cancer, as well as the rationale for their development. RECENT FINDINGS: Several proangiogenic factors may be potential targets for antiangiogenic therapy in ovarian cancer. Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been evaluated as a single agent in two phase II clinical trials and in combination with chemotherapy in three phase II studies, with promising results. This agent is also being evaluated in association with chemotherapy in two phase III clinical trials, both in the treatment and in the maintenance settings. Heparanase inhibitors and inhibitors of platelet-derived growth factor signalling remain as potential agents to be investigated in phase II trials. The development of biomarkers to define appropriate dosing regimens and predict which patients may benefit from antiangiogenic therapies is of great importance. SUMMARY: Data from preclinical and clinical studies reported in the last 2 years demonstrate the importance of several proangiogenic factors in the prognosis of ovarian cancer, suggesting possible new targets for antiangiogenic therapy. The agents that are currently being investigated in phase II and III clinical trials include bevacizumab, erlotinib, sunitinib, sorafenib and vascular endothelial growth factor Trap, and the results of these trials will have significant implications in the future management of ovarian cancer.
CitationAntiangiogenic therapy for ovarian cancer. 2007, 19 (5):497-505 Curr Opin Oncol
JournalCurrent Opinion In Oncology
- Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
- Authors: Teoh D, Secord AA
- Issue date: 2012 Mar
- Antiangiogenic therapies in epithelial ovarian cancer.
- Authors: Teoh DG, Secord AA
- Issue date: 2011 Jan
- Where do antiangiogenic agents belong in the treatment algorithm for ovarian cancer?
- Authors: Dizon DS
- Issue date: 2013 Oct
- Current status of anti-angiogenic agents in the treatment of ovarian carcinoma.
- Authors: Sánchez-Muñoz A, Pérez-Ruiz E, Mendiola Fernández C, Alba Conejo E, González-Martín A
- Issue date: 2009 Sep
- Targeted agents in ovarian cancer.
- Authors: Kristedja TS, Morgan RJ, Cristea M
- Issue date: 2010 Sep